DEINOVE: DNV3837 Antibiotic Candidate: the Phase II Trial Continues in the United States, Despite a Disrupted Context Due to The COVID-19 Outbreak
(WorldNews France)

DEINOVE: DNV3837 Antibiotic Candidate: the Phase II Trial Continues in the United States, Despite a Disrupted Context Due to The COVID-19 Outbreak 15 Jul 2020 18:30 CEST Company Name DEINOVE ISN FR0010879056 Market Euronext Growth Symbol ALDEI Regulatory News: DEINOVE (Paris:ALDEI) (Euronext Growth Paris: ALDEI), a French biotech company that uses its lead generation platform to develop innovative anti-infective drugs, is pursuing the Phase II clinical trial of its antibiotic candidate DNV3837, in a context where U.S. hospitals are still fighting the COVID-19 pandemic. The Company thanks the clinicians for their commitment to this trial, as they face an unprecedented health crisis. DNV3837...